Overview

Rivaroxaban Versus Warfarin for Thromboprophylaxis in Children With Giant Coronary Aneurysms After Kawasaki Disease

Status:
Not yet recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of rivaroxaban compared to warfarin for thromboprophylaxis in children with giant coronary aneurysms after Kawasaki disease

Phase:

Phase 3

Details

Lead Sponsor:

Children's Hospital of Fudan University

Treatments:

Aspirin
Clopidogrel
Rivaroxaban
Vitamin K
Warfarin